Pyxis Oncology

PYXS
1.8107.74% ( +0.130 )
Closed: Nov 20, 16:00:00 (EDT)

Financials

Q3 FY2026 EarningsQ3 FY26 results beat consensus on EPS and profitability despite continued zero revenue. GAAP EPS was -$0.24 vs. -$0.28 expected, and EBIT loss of -$20.5M was narrower than the anticipated -$24.5M loss, driven by reduced manufacturing costs and lower stock-based compensation. The company significantly bolstered its liquidity post-quarter via a $110M public offering, extending its cash runway into H1 2028 and alleviating previous going concern uncertainties.

Financial report interval: 2026.06.30 - 2026.09.30

Overview: Pyxis Oncology(PYXS) the EBIT is -20.52 M (+12.52%), Beat estimate;the EPS is -0.24 (+31.43%), Beat estimate.

Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.02B12.52%
-0.02B4.39%
+0.00B16.91%
EPSExceed expectations
-0.2431.43%
-0.275721.23%
+0.035710.20%

Upcoming earnings report - FY2026 Annual Earning Release

Available dateMar 19, 2027
Estimate Revenue19.44K
Estimate EBIT-93.64M
Estimate EPS-1.1042

Revenue

ActualEstimateUnit: USD
Quarterly

EBIT

ActualEstimateUnit: USD
Quarterly

Net income

ActualEstimateUnit: USD
Quarterly

EPS

ActualEstimateUnit: USD
Quarterly